株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ホスホジエステラーゼ(PDE)阻害剤の世界市場:2019年~2023年

Global Phosphodiesterase (PDE) inhibitors Market 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 891069
出版日 ページ情報 英文 134 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.83円で換算しております。
ホスホジエステラーゼ(PDE)阻害剤の世界市場:2019年~2023年 Global Phosphodiesterase (PDE) inhibitors Market 2019-2023
出版日: 2019年07月12日 ページ情報: 英文 134 Pages
概要

ホスホジエステラーゼ阻害剤は、同様の作用機序を有する、すなわちPDE酵素を阻害することによる、薬物を含む薬物クラスを指しています。2018年、経口セグメントが最大の市場シェアを獲得しており、この傾向は予測期間中も続くと予想されます。低コスト、正確な投与量と安定性などの要因は、市場ポジションを維持するために経口セグメントで重要な役割を果たします。また、世界のホスホジエステラーゼ阻害剤市場では、貧弱な生活習慣の採用の増加、勃起不全(ED)の罹患率の上昇、および次世代のPDE阻害剤の入手可能性などが成長要因となっており、予測期間中に約6%のCAGRで成長する見込みです。しかし、PDE阻害剤の強力な薬物相互作用、PDE阻害剤に関連する副作用、および後発品の発売により、予測期間にわたるホスホジエステラーゼ阻害剤産業の成長が阻害される可能性があります。

当レポートでは、世界のホスホジエステラーゼ(PDE)阻害剤市場について調査分析し、市場規模および成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 パイプライン情勢

第7章 市場セグメンテーション:アプリケーション別

  • 市場セグメンテーション:アプリケーション別
  • アプリケーション別比較:市場規模および予測(2018年~2023年)
  • 経口
  • 局所
  • その他の投与ルート
  • 市場機会:アプリケーション別

第8章 顧客情勢

第9章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第10章 意思決定の枠組み

第11章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第12章 市場動向

  • PDE阻害剤開発のための新しい技術の適用
  • 高齢者人口の増加
  • 慢性疾患の負担の増加

第13章 ベンダー情勢

  • 概要
  • 創造的破壊の状況
  • 競合シナリオ

第14章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Bayer AG
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Vivus Inc.

第15章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義

第16章 TECHNAVIOについて

図表
  • Exhibit 1: Global pharmaceuticals market
  • Exhibit 2: Segments of global pharmaceuticals market
  • Exhibit 3: Market characteristics
  • Exhibit 4: Market segments
  • Exhibit 5: Some of the commercially available PDE inhibitors
  • Exhibit 6: Disease targets for different PDE inhibitors
  • Exhibit 7: Market definition - Inclusions and exclusions checklist
  • Exhibit 8: Market size 2018
  • Exhibit 9: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 11: Five forces analysis 2018
  • Exhibit 12: Five forces analysis 2023
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2018
  • Exhibit 19: Some of the phase III clinical trials of PDE inhibitors
  • Exhibit 20: Application - Market share 2018-2023 (%)
  • Exhibit 21: Comparison by application
  • Exhibit 22: Oral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Advantages of tablet dosage form
  • Exhibit 24: Oral - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Topical - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 26: Topical - Year-over-year growth 2019-2023 (%)
  • Exhibit 27: Other RoA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: Other RoA - Year-over-year growth 2019-2023 (%)
  • Exhibit 29: Market opportunity by application
  • Exhibit 30: Customer landscape
  • Exhibit 31: Market share by geography 2018-2023 (%)
  • Exhibit 32: Geographic comparison
  • Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in North America
  • Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in Europe
  • Exhibit 39: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 40: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 41: Top 3 countries in Asia
  • Exhibit 42: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 43: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 44: Top 3 countries in ROW
  • Exhibit 45: Key leading countries
  • Exhibit 46: Market opportunity
  • Exhibit 47: Role of PDE5 inhibitors in ED
  • Exhibit 48: Sales of PDE5 inhibitors after the launch of generics ($ millions)
  • Exhibit 49: Impact of drivers and challenges
  • Exhibit 50: CDC statistics about chronic diseases in geriatric population in the US over the past few years
  • Exhibit 51: Geriatric population scenario in the US
  • Exhibit 52: Vendor landscape
  • Exhibit 53: Landscape disruption
  • Exhibit 54: Vendors covered
  • Exhibit 55: Vendor classification
  • Exhibit 56: Market positioning of vendors
  • Exhibit 57: Bayer AG - Vendor overview
  • Exhibit 58: Bayer AG - Product segments
  • Exhibit 59: Bayer AG - Organizational developments
  • Exhibit 60: Bayer AG - Geographic focus
  • Exhibit 61: Bayer AG - Segment focus
  • Exhibit 62: Bayer AG - Key offerings
  • Exhibit 63: Bayer AG - Key customers
  • Exhibit 64: Eli Lilly and Co. - Vendor overview
  • Exhibit 65: Eli Lilly and Co. - Business segments
  • Exhibit 66: Eli Lilly and Co. - Organizational developments
  • Exhibit 67: Eli Lilly and Co. - Geographic focus
  • Exhibit 68: Eli Lilly and Co. - Segment focus
  • Exhibit 69: Eli Lilly and Co. - Key offerings
  • Exhibit 70: Eli Lilly and Co. - Key customers
  • Exhibit 71: GlaxoSmithKline Plc - Vendor overview
  • Exhibit 72: GlaxoSmithKline Plc - Business segments
  • Exhibit 73: GlaxoSmithKline Plc - Organizational developments
  • Exhibit 74: GlaxoSmithKline Plc - Geographic focus
  • Exhibit 75: GlaxoSmithKline Plc - Segment focus
  • Exhibit 76: GlaxoSmithKline Plc - Key offerings
  • Exhibit 77: GlaxoSmithKline Plc - Key customers
  • Exhibit 78: Pfizer Inc. - Vendor overview
  • Exhibit 79: Pfizer Inc. - Business segments
  • Exhibit 80: Pfizer Inc. - Organizational developments
  • Exhibit 81: Pfizer Inc. - Geographic focus
  • Exhibit 82: Pfizer Inc. - Segment focus
  • Exhibit 83: Pfizer Inc. - Key offerings
  • Exhibit 84: Pfizer Inc. - Key customers
  • Exhibit 85: Vivus Inc. - Vendor overview
  • Exhibit 86: Vivus Inc. - Business segments
  • Exhibit 87: Vivus Inc. - Organizational developments
  • Exhibit 88: Vivus Inc. - Geographic focus
  • Exhibit 89: Vivus Inc. - Key offerings
  • Exhibit 90: Vivus Inc. - Key customers
  • Exhibit 91: Validation techniques employed for market sizing
  • Exhibit 92: Definition of market positioning of vendors
目次
Product Code: IRTNTR31686

About this market

Phosphodiesterase inhibitors represent a drug class comprising drugs with a similar mechanism of action i.e. by inhibiting PDE enzymes. Technavio's phosphodiesterase inhibitors market analysis considers sales from oral, topical, and other RoA. Our analysis also considers the sales of phosphodiesterase inhibitors in Asia, Europe, North America, and ROW. In 2018, the oral segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as low cost, and accurate dosage and stability will play a significant role in the oral segment to maintain its market position. Also, our global phosphodiesterase inhibitors market report also looks at factors such as growing adoption of poor lifestyle habits, rising prevalence of erectile dysfunction (ED), and availability of next-generation PDE inhibitors. However, potent drug interactions of PDE inhibitors, side-effects associated with PDE inhibitors, and launch of generics may hamper the growth of the phosphodiesterase inhibitors industry over the forecast period.

Overview

Rising prevalence of erectile dysfunction (ED)

The etiology of ED can be attributed to multiple factors, such as diabetes mellitus, testosterone deficiency, prostate cancer, obesity, hypertension, and hyperlipidemia. In addition, the consumption of certain medicines and substance abuse can lead to ED. As most of these factors are related to lifestyle changes, the prevalence of ED is increasing globally. Rapid urbanization, and the inherent lifestyle changes, along with high stress at the workplace are rendering young men more susceptible to ED. Thus, the increase in the incidence of ED is expected to boost the adoption of PDE inhibitors and drive the market at a CAGR of almost 6% during the forecast period.

Rising burden of chronic diseases

Chronic diseases are among the leading causes of death and contribute to a significant portion of annual healthcare expenditure. Rising healthcare costs associated with chronic diseases such as heart disease, stroke, diabetes and prediabetes is expected to lead to an increase in the adoption of PDE5 inhibitors. Thus, an increase in the economic and health burden of these diseases will ensure continuous or increased use of PDE5 inhibitors for their remission, which will promote market growth during the forecast period.

For the detailed list of factors that will drive the global phosphodiesterase inhibitors market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global phosphodiesterase inhibitors market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading phosphodiesterase inhibitors manufacturers, that include Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, Pfizer Inc., Vivus Inc.

Also, the phosphodiesterase inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE LANDSCAPE

PART 07: MARKET SEGMENTATION BY APPLICATION

  • Market segmentation by application
  • Comparison by application
  • Oral - Market size and forecast 2018-2023
  • Topical - Market size and forecast 2018-2023
  • Other RoA - Market size and forecast 2018-2023
  • Market opportunity by application

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Application of novel technologies for PDE inhibitors development
  • Growing geriatric population
  • Rising burden of chronic diseases

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer AG
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Vivus Inc.

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO